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Abstract
Background: Pyrazinamide (PZA) is a key component of current and future regimens for tuberculosis (TB). Inclusion
of PZA at higher doses and for longer durations may improve efficacy outcomes but must be balanced against the
potential for worse safety outcomes.
Methods: We will search for randomised and quasi-randomised clinical trials in adult participants with and without the
inclusion of PZA in TB treatment regimens in the Cochrane infectious diseases group’s trials register, Cochrane central
register of controlled trials (CENTRAL), MEDLINE, EMBASE, LILACS, the metaRegister of Controlled Trials (mRCT) and the
World Health Organization (WHO) international clinical trials registry platform. One author will screen abstracts and
remove ineligible studies (10% of which will be double-screened by a second author). Two authors will review full texts
for inclusion. Safety and efficacy data will be extracted to pre-piloted forms by one author (10% of which will be
double-extracted by a second author). The Cochrane risk of bias tool will be used to assess study quality. The study has
three objectives: the association of (1) inclusion, (2) dose and (3) duration of PZA with efficacy and safety outcomes.
Risk ratios as relative measures of effect for direct comparisons within trials (all objectives) and proportions as absolute
measures of effect for indirect comparisons across trials (for objectives 2 and 3) will be calculated. If there is insufficient
data for direct comparisons within trials for objective 1, indirect comparisons between trials will be performed.
Measures of effect will be pooled, with corresponding 95% confidence intervals and p values. Meta-analysis will be
performed using the generalised inverse variance method for fixed effects models (FEM) or the DerSimonian-Laird
method for random effects models (REM). For indirect comparisons, meta-regression for absolute measures against
dose and duration data will be performed. Heterogeneity will be quantified through the I2-statistic for direct
comparisons and the τ2 statistic for indirect comparisons using meta-regression.
Discussion: The current use of PZA for TB is based on over 60 years of clinical trial data, but this has never been
synthesised to guide rationale use in future regimens and clinical trials.
Systematic review registration: International Prospective Register of Systematic Reviews (PROSPERO) CRD42019138735
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Background
Pyrazinamide (PZA) is a key component of modern ther-
apy for tuberculosis (TB). It is considered an essential
first-line drug and may also be used as part of treatment
for multi-drug resistant disease (MDR TB). First intro-
duced in the 1950s, its mechanism of action remains
poorly understood and appears to be highly dependent
on ambient pH at the site of action. PZA may be a pro-
drug, undergoing conversion in vivo to pyrazinoic acid
(POA) [1]. Resistance to PZA is correlated with numer-
ous mutations in the mycobacterial pncA gene which
codes for an amidase enzyme, PZAse, responsible for the
conversion of PZA to POA [2]. Initial development of
PZA suggested that it was associated with significant
hepatotoxicity at the doses used [3]. Subsequent clinical
trials in drug-sensitive TB (DS-TB) using a lower dose of
PZA in conjunction with rifampicin demonstrated that it
had an important role to play in shortening treatment,
appearing to be particularly active during the first 2
months of treatment [4]. In multidrug resistant TB
(MDR-TB), by contrast, PZA has been used in the ab-
sence of rifampicin for the duration of treatment and
one-third to two-thirds of isolates are resistant to PZA
in most series [5]. There has been renewed interest in
optimising current DS-TB treatment, and a number of
observational and randomised studies aim to identify the
most efficacious regimens for MDR TB. Several lines of
evidence suggest that increasing the PZA dose may be
one route to these goals. In a murine model, increasing
exposure to PZA up to fourfold (by increasing dose)
resulted in improved reductions in mycobacterial load
[6]. In patients, current dosing guidelines result in below
‘target’ concentrations, with low PZA exposure predict-
ing clinical outcome [7]. At least some of the studies
which demonstrated PZA’s treatment-shortening effect
used milligram per kilogram (mg/kg) doses roughly
double those in use today [8, 9]. Interest in optimising
TB regimens by increasing the dose of PZA are
tempered by concerns about hepatotoxicity and other
adverse events. However, few formal dose-ranging stud-
ies of PZA have been reported, and there has been no
evaluation of the risk-benefit of the drug at differing
doses. Moreover, the contribution of pyrazinamide to
both efficacy and hepatotoxicity may be correlated to
total exposure, and hence the interaction between dose
and duration may be important in making these risk-
benefit analyses [10, 11]. Despite the potential import-
ance of the question, no complete synthesis and analysis
of the contribution of PZA inclusion, dose and duration
to efficacy and safety outcomes in TB (of all resistance
patterns) are available. We aim to perform a systematic
review and meta-analysis of existing clinical trials in
order to address these questions. One meta-analysis ad-
dressing the impact of PZA inclusion and dose on safety
outcomes only was published almost a decade ago, but
did not examine the trade-off with efficacy, identified
only 29 eligible studies (our data suggest there are far
more potentially eligible studies) [12] and made no
adjustments for the rest of the drug regimens [13]. We
hope that this work will form part of the basis for use,
optimal dose and duration of PZA in clinical trials of
both DS-TB and MDR-TB.
Objectives
We aim to determine whether the following are associ-
ated with improved efficacy or worse safety outcomes
during treatment of tuberculosis using first- or second-
line regimens:
1. Inclusion of PZA
2. Dose of PZA
3. Duration of PZA
Methods
This review will be conducted in accordance with the
PRISMA statement [14]; a completed copy of the
PRISMA-P checklist is provided in Additional file 1.
Eligibility criteria
For efficacy outcomes, we will include randomised con-
trolled trials and quasi-randomised controlled trials in
adults with pulmonary tuberculosis (based on a micro-
biological diagnosis of a positive sputum smear for acid
fast bacilli (AFB) or mycobacterial culture) whether fully
drug-sensitive, isoniazid-resistant or MDR-TB. For safety
outcomes, we considered that a microbiological diagno-
sis was not required, and so trials with clinical and
extra-pulmonary diagnoses of TB will be included in
addition. To address the objectives of this study, trials
will be included if they include anti-tuberculosis regi-
mens containing PZA and/or allow at least one of the
following three comparisons:
1. For objective 1 (inclusion vs. non-inclusion of
PZA): anti-tuberculosis treatment regimens which
do not contain PZA (among which may be regi-
mens considered otherwise ‘identical’: the same
drugs at the same doses administered for a similar
cumulative dose if given at different intervals).
2. For objective 2 (dose of PZA): anti-tuberculosis
treatment regimens containing PZA at different
doses.
3. For objective 3 (duration of PZA): anti-tuberculosis
treatment regimens in which PZA is administered
for different durations (among which PZA duration
may be considered ‘identical’, if administered for a
similar cumulative dose during that interval).
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Types of outcomes
Efficacy and safety outcomes will be assessed as follows:
Primary–efficacy (as per reference [12])
 Treatment failure—mycobacterial culture positive at
completion of treatment protocol
 Relapse—mycobacterial culture-negative at completion
of treatment protocol but culture-positive during post-
treatment follow-up period
Primary–safety
 Adverse events
 Serious adverse events (as defined by the
investigators)
 Discontinuation of PZA
 Regimen switch
 Deaths (all cause)
 Deaths (due to tuberculosis)
Secondary–safety
 Investigator-defined drug-induced liver injury (DILI)
(whether biochemical or clinical)
 Arthralgia and joint effusions
Information sources and search strategy
We will search for studies meeting the eligibility criteria
in the Cochrane infectious diseases group’s trials register
(2019), Cochrane central register of controlled trials
(CENTRAL, published in The Cochrane Library), MED-
LINE (1950 to December 2019), EMBASE (1975 to
December 2019) and LILACS (1982 to December 2019).
The search strategy is designed to be inclusive and iden-
tify all eligible clinical trials in tuberculosis with or with-
out the inclusion of PZA as follows.
1) Tuberculosis AND clinical trials
2) Rifampicin OR isoniazid OR pyrazinamide OR
ethambutol OR thiacetazone OR para-
aminosalicylic acid OR streptomycin OR rifabutin
OR rifapentine OR levofloxacin OR ofloxacin OR
gatifloxacin OR moxifloxacin OR bedaquiline OR
pretomanid
3) 1 AND 2
In addition, we will search the metaRegister of
Controlled Trials (mRCT) and the World Health
Organization (WHO) international clinical trials registry
platform using ‘tuberculosis’ as the search term. We will
not exclude studies based on language of publication.
All studies regardless of publication status (published,
unpublished, in press and in progress) will be eligible.
We will hand search the reference lists of included
studies and relevant reviews to identify other potentially
eligible studies.
Study selection and data extraction
A complete list of studies identified by the search strat-
egy will be compiled and duplicates removed. One
author (AM) will review the abstracts of all identified
studies and remove ineligible studies, with 10% of ab-
stracts being double-screened by a second author (JM).
The full text for remaining potentially eligible studies
will be accessed and reviewed by two authors (AM and
JM) for inclusion. Any disagreements on eligibility will
be resolved by discussion or referral to a third author
(GD). Efficacy data has already been independently ex-
tracted by two authors (LB and GD) until November
2016 using a standardised electronic data extraction
form. Data was collected, and inconsistent data record-
ing was resolved through discussion and contacting the
author where necessary. This search and extraction will
be updated until December 2019 following the same
methodology by a single author (AM), with 10% double-
extracted by a second author (JM) to check for
consistency. Additional safety data for all studies will be
extracted to a pre-piloted supplementary electronic data
extraction form for more detailed safety outcomes by a
single author (AM) and 10% double-extracted by a sec-
ond author (JM). We will collect data on study design,
included participants, treatment regimens, outcomes and
selected other data. Study authors will be contacted
when the study report does not provide sufficient infor-
mation concerning the study methods, treatment effect
sizes or numbers of outcomes for each treatment arm.
All extracted data will be entered into a spreadsheet.
Quality assessment
Bias will be assessed using the Cochrane risk of bias tool
to assess the following source of bias domains: (1) selec-
tion bias (biased allocation to interventions) via assess-
ment of adequate sequence generation in the allocation
of participants to intervention and control groups and
adequate allocation concealment, (2) performance bias
via assessment of blinding of personnel and participants
to treatment allocation, (3) detection bias via assessment
of blinding of the outcome assessor to treatment alloca-
tion, (4) reporting bias via assessment of selective out-
come reporting, (5) attrition bias via assessment of the
description of participants not included versus those
included in the final analysis.
Data analysis
We will calculate risk ratios as relative measures of effect
for direct comparisons within trials (for all objectives)
and proportions as absolute measures of effect for indir-
ect comparisons across trials (for objectives 2 and 3
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only). If there is insufficient data for direct comparisons
within trials for objective 1, indirect comparisons
between trials will be performed. Statistical analysis will
be conducted using R for Windows, version 3.6.0. Rela-
tive and absolute measures of effect will be pooled and
analysed using the package metafor. Meta-analysis will
be performed using the generalised inverse variance
method for fixed effects models (FEM) or the
DerSimonian-Laird method for random effects models
(REM) [15]. Forest plots will be generated for relative
measures using metafor and absolute measures using
custom code. Corresponding 95% confidence intervals
(CIs) and p values will be calculated; results will be
deemed statistically significant at p < 0.05. Meta-
regression will be performed for absolute measures
against categorised dose and duration data, including
their interaction. For direct comparisons, we will quan-
tify the level of the observed heterogeneity through the
I2-statistic. For indirect comparisons using meta-
regression, the τ2 statistic will be used to assess
heterogeneity. We will perform the following sensitivity
analyses where appropriate: (1) intention to treat (ITT,
where all participants that were randomised are in-
cluded), (2) per protocol (PP, where only those partici-
pants that were randomised and completed the
treatment course as planned are included), (3) worst-
case scenario (where participants missing an outcome
are assumed to have failed or relapsed for efficacy
outcomes or had a negative safety outcome) and (4)
best-case scenario (where participants missing an out-
come are assumed to have favourable efficacy and safety
outcomes).
Subgroup analyses
Contingent on sufficient studies, we plan to explore the
following subgroups:
 HIV co-infected versus non-infected participants
 Geographical location of study (we anticipate this
will be on a regional basis, dependant on the
number of included studies from different locations)
 Symptomatic versus asymptomatic DILI
 DILI defined as alanine aminotransferase (ALT):
aspartate aminotransferase (AST) ratio > 5 vs.
ALT:AST ratio > 3
If the I2 value is over 40% and there are sufficient
studies, we will explore sources of heterogeneity by
stratifying on study-level characteristics including aver-
age number of drugs included in treatment regimens,
use of fluoroquinolones, use of rifampicin, average num-
ber of drugs to which isolates show resistance, number
of patients previously treated for TB, extent of disease
and study quality.
Assessment of publication bias
Funnel plots and Galbraith plots will be produced for all
outcomes where numbers of trials (> 10) permit.
Protocol and registration
This review has been registered with the International
Prospective Register of Systematic Reviews (PROS-
PERO); number CRD42019138735.
Discussion
This systematic review and meta-analysis will be the
first, to our knowledge, to examine the trade-off between
efficacy and safety in the use of PZA in TB, irrespective
of resistance pattern. PZA is an old TB drug, but one
that is likely to remain important in current and future
regimens for TB and has been used in a wealth of clin-
ical trials over the last 60 years. Correctly synthesised,
this data provides the opportunity for the more rational
use of PZA in future regimens and clinical trials, and
hence this review has the potential for wide application.
The principal practical and operational issues we foresee
in this systematic review and meta-analysis of clinical
trials spanning many years of publication are poor qual-
ity trials and heterogenous interventions and outcome
reporting [12]. Nonetheless, this data is currently used in
TB drug regimen policy-setting in a non-systematic
manner, and we have planned our analysis in a rigorous
manner to make the best use of this data.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-019-1231-1.
Additional file 1. PRISMA-P checklist.
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